0.00Open2.30Pre Close0 Volume25 Open Interest2.50Strike Price0.00Turnover402.85%IV8.35%PremiumDec 20, 2024Expiry Date1.93Intrinsic Value100Multiplier16DDays to Expiry0.37Extrinsic Value100Contract SizeAmericanOptions Type0.8621Delta0.0591Gamma1.93Leverage Ratio-0.0258Theta0.0007Rho1.66Eff Leverage0.0020Vega
Aquestive Therapeutics Stock Discussion
1 min ago
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms Nda Submission Guidance for Anaphylm™ (Epinephrine) Sublingual Film
Doesn't make sense to me?
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
Aquestive Therapeutics (NASDAQ: AQST) announced positive topline results from its Oral Allergy Syndrome (OAS) challenge study for Anaphylm™ sublingual film. The study met both primary and secondary endpoints, demonstrating rapid symptom resolution beginning two minutes after administration. The median time for...
Aquestive Therapeutics Inc - Oas Challenge Study Meets Primary and Secondary Endpoints
No comment yet